Clinical trials: Psychotic Symptoms
Mental Disorder
Package of Community-based Mental Healthcare Services in Preventing Perinatal Mental Disorders
During pregnancy and in the year after birth women can be affected by a range of mental health problems. Anxiety and depression are the most prevalent mental illnesses during the perinatal period.
- Trial name
- NCT03678415
- Testing
- Community-Based Primary Mental Health Care (CBPMHC) package
- Where
- Bangladesh
- Volunteers
- 1,210 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Schizophrenia, Psychosis
Enhancing Rehabilitation for Veterans With Serious Mental Illness
This study addresses the critical need for innovative therapeutic interventions in Veterans with serious mental illnesses (SMI) receiving care in VA Psychosocial Rehabilitation and Recovery Centers (PRRCs).
- Conditions
- Schizophrenia, Psychosis, Serious Mental Illness, PTSD
- Trial name
- NCT06586164
- Testing
- Targeted Cognitive Training
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Aging
Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia
The 2020 NIMH Strategic Plan for Research calls for investigations targeting neurobiology of mental illness across the lifespan.
- Conditions
- Schizophrenia, Aging, Disease Course, Biomarker
- Trial name
- NCT04951700
- Testing
- Other
- Where
- United States
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia, Negative Symptoms of Schizophrenia
Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
"Negative" symptoms are a major challenge for people with schizophrenia (SZ) and are a key reason why they struggle with everyday functioning.
- Trial name
- NCT07356765
- Testing
- Berberine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Anding Hospital
Schizophrenia
Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
This is a study of a new medication for the treatment of cognitive impairments (thinking difficulties) and negative symptoms in people with schizophrenia. The new medication is rasagiline.
- Trial name
- NCT00492336
- Testing
- rasagiline (Pharmacodynamics)
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- University of Maryland, Baltimore
Panic Disorder, Anxiety Disorder
Treatment of Panic Disorder Among Individuals Consulting Emergency Departments for Non Cardiac Chest Pain
The purpose of this study is to assess the impact of three different treatment modalities on panic symptoms, quality of life and use of health services among individuals consulting an emergency department for non cardiac chest…
- Conditions
- Panic Disorder, Anxiety Disorder, Mental Disorder
- Trial name
- MADONA (NCT00736346)
- Testing
- Brief cognitive-behavioral treatment for Panic Disorder, Cognitive-Behavior Therapy for Panic Disorder, paroxetine
- Where
- 3 sites in Canada
- Volunteers
- 204 people
- Sponsor
- Université du Québec a Montréal
Schizophrenia, Depression
Characterization of the Motivational Deficit in Schizophrenia and Depression
This research focuses on disorders of motivation, responsible for a disability that patients experience daily. It is a disorder that affects behavior, especially social.
- Trial name
- SCHIZOBAT (NCT02378818)
- Testing
- Force task, preference task, discount task, learning task.
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Delirium, Agitated Behavior
Trial of Safety Nets In Hospitalized Patients
This study compared standard hospital restraints to a newer safety net restraint system to compare them for acceptability, tolerance, duration of restrain, length of stay in the hospital, and satisfaction of MD, nurse, and…
- Conditions
- Delirium, Agitated Behavior, Alcohol Withdrawl, Acute Confusional State
- Trial name
- NCT00409370
- Testing
- SOMA safe enclosure
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Griffin Hospital
Mental Disorder, Depression
Screening to Identify Parents in Need of Mental Health Support: A Feasibility Study in Child Welfare Services
The main aim of this study is to evaluate the feasibility, preliminary effects and experiences of the Collaboration-Screening-Referral approach (CSR / in Swedish: Samverkan-Screening-Hänvisning - SSH) when used with parents…
- Conditions
- Mental Disorder, Depression, Anxiety, Child Abuse
- Trial name
- NCT06600139
- Testing
- The Collaboration-Screening-Referral (SSH) model
- Where
- Sweden
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Psychosis
A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine
The investigators are going to observe if add-on of n-acetylcysteine (NAC) 1200 or 2400 mg/d during tapering of antipsychotics in patients with remitted psychosis can help to reduce the pre-requisite of stabilization to 3 months…
- Trial name
- NCT06546475
- Testing
- N-Acetylcysteine
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
This study is open to people aged 18 years or older with schizophrenia. People can join the study if they are willing to use a smartphone app called CT-155.
- Trial name
- NCT06791122
- Testing
- Digital therapeutic (CT-155)
- Where
- 31 sites in United States
- Volunteers
- 262 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Antipsychotic Augmentation With L-Dopa
Dopamine, a chemical in the brain, has been linked to schizophrenia for a number of years. More recently, there is evidence that certain areas affected in schizophrenia (e.g.
- Trial name
- NCT01636037
- Testing
- levodopa/carbidopa (generic version of Sinemet)
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Centre for Addiction and Mental Health
Healthy
A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
This is a 28-day, single-center, double-blind, placebo-controlled inpatient study of the administration of risperidone alone or in combination with mifepristone in healthy adult male volunteers to determine the average change in…
- Trial name
- NCT00698022
- Testing
- Risperidone, Mifepristone
- Where
- India
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Schizophrenia, Psychotic Disorders
Tocilizumab in Schizophrenia
This study is a Phase 1 clinical trial to determine the safety, tolerability, and efficacy of Tocilizumab (Actemra) as an adjunct to antipsychotic medications in stable outpatients with schizophrenia.
- Trial name
- NCT02874573
- Testing
- Tocilizumab, Normal saline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brian Miller
Encephalopathy, Psychosis
Neuroimmunology Registry and Biobank
A variety of antineuronal antibodies have been detected in the cerebrospinal fluid (CSF) of patients with neurological diseases.
- Conditions
- Encephalopathy, Psychosis, Impaired Consciousness, Epilepsy
- Trial name
- NCT06958341
- Where
- 2 sites in Germany
- Volunteers
- 300 people
- Sponsor
- Charite University, Berlin, Germany
Schizophrenia
Brain Stimulation, Clinical Symptoms and Cognition
The purpose of this study is to test the impact of non-invasive brain stimulation, transcranial direct current stimulation (tDCS), on auditory hallucinations, negative symptoms and cognition in schizophrenia.
- Trial name
- NCT05053451
- Testing
- Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Schizophrenia and Predominant Negative Symptoms
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predominant negative symptoms, as…
- Trial name
- NCT00922272
- Testing
- SPD489 (lisdexamfetamine dimesylate)
- Where
- 27 sites in United States
- Volunteers
- 92 people
- Sponsor
- Shire
Schizophrenia
Effect of Metacognitive Therapy on Negative Symptoms: a Case Series
Negative symptoms (e.g. diminished pleasure and motivation) are common in people with a diagnosis of schizophrenia. Little is known about the psychological mechanisms involved in negative symptom development and maintenance and…
- Trial name
- NCT03999112
- Testing
- Metacognitive Reflection and Insight Therapy (MERIT)
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- NHS Greater Glasgow and Clyde
Schizophrenia
Staccato Loxapine in Agitation (Proof of Concept)
The purpose of this study is to assess efficacy and safety of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients.
- Trial name
- NCT00369577
- Testing
- Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Schizophrenia, Parkinson Disease
Sound and Vision: A Collaboration Between Service-users, Artists and the Public to Explore the Lived Experience of Hallucinations
Sound and Vision: A collaboration between service-users, artists and the public to explore the lived experience of hallucinations
- Conditions
- Schizophrenia, Parkinson Disease, Hallucinations
- Trial name
- NCT04399096
- Where
- 2 sites in United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Cambridge
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.